CClinicalTrials.gg
CompletedNCT01494441Updated May 17, 2023

Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease

An interventional study of rhBMP-2/BCP and rhBMP-2/BCP/TSRH® Spinal System in Degenerative Disc Disease, sponsored by Medtronic Spinal and Biologics. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Medtronic Spinal and Biologics · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this pilot clinical trial is to evaluate both device designs (rhBMP-2/BCP and rhBMP-2/BCP/TSRH® spinal System) as methods of facilitating spinal fusion as compared to instrumented fusion with autograft in patients with symptomatic degenerative disc disease.

02

Conditions studied

  • Degenerative Disc Disease

Keywords

  • lumbar degenerative disc disease
03

In context

Spinal Diseases

267 studies on the registry are indexed under Spinal Diseases; 54 are open to participants now.

This study's enrollment of 27 is below the median of 52 across 166 interventional studies indexed under Spinal Diseases.

Browse Spinal Diseases studies →

Lead sponsor

Medtronic Spinal and Biologics is the lead sponsor of 56 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Has degenerative disc diseases noted by back pain of discogenic origin,with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain [leg, back, or symptoms in the sciatic nerve distribution] function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray,etc.) to include one or more of the following:

    • instability (defined as angular motion > 5° and/or translation > 4 mm, based on Flex/Ext radiographs);
    • osteophyte formation;
    • decreased disc height;
    • thickening of ligamentous tissue;
    • disc degeneration or herniation; and/or
    • facet joint degeneration.
  2. Has preoperative Oswestry score > 30.
  3. Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW,1932.).
  4. Requires fusion of a single level disc space from L1 to S1.
  5. Is at least 18 years of age, inclusive, at the time of surgery.
  6. Has not responded to non-operative treatment ( e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
  7. If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
  8. Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.

Exclusion criteria

Exclusion Criteria:

  1. Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade1 or less spondylolisthesis at the involved level.
  2. Had previous spinal fusion surgical procedure at the involved level.
  3. Require spinal fusion at more than one lumbar level.
  4. Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
  5. Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
  6. Has presence of active malignancy.
  7. Has overt or active bacterial infection, either local or systemic.
  8. Is grossly obese, i.e., weight > 40% over ideal for their age and height.
  9. Has fever ( temperature >101°F oral) at the time of surgery.
  10. Has a documented titanium alloy allergy or intolerance.
  11. Is mentally incompetent. If questionable, obtain psychiatric consult.
  12. Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
  13. Is a prisoner.
  14. Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
  15. Is a tobacco user at the time of surgery.
  16. Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., NSAIDS, steroids or methotrexate).
  17. Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
  18. Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).
  19. Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.
  20. Has received any previous exposure to any/all BMPs of either human or animal extraction.
  21. Has a history of severe allergy (anaphylaxis).
  22. Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    rhBMP-2/BCP

    Procedure: rhBMP-2/BCP

  • Experimental
    rhBMP-2/BCP/TSRH® Spinal System

    Device: rhBMP-2/BCP/TSRH® Spinal System

  • Active comparator
    Autograft/TSRH® Spinal System

    Device: Autograft/TSRH® Spinal System

Interventions

  • ProcedurerhBMP-2/BCP

    The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.

    Also known as: recombinant human Bone Morphogenetic Protein-2, biphasic calcium phosphate

  • DevicerhBMP-2/BCP/TSRH® Spinal System

    rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.

    Also known as: recombinant human Bone Morphogenetic Protein-2, biphasic calcium phosphate

  • DeviceAutograft/TSRH® Spinal System

    The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.

    Also known as: Autograft

06

What researchers measure

Primary outcomes

  1. Fusion

    Fusion is defined as: 1. Evidence of bridging trabecular bone. 2. No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographs determined by superimposing the two views, one upon the other; b. Less than 5° difference in angular motion between flexion and extension as seen on the lateral flexion/extension radiographs; 3. Absence of radiolucent lines completely through the fusion mass.

    Time frame: 24 month

  2. Pain/Disability Status

    The self-administered Oswestry Low Back pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score \>= 15

    Time frame: 24 month

Secondary outcomes

  1. Neurological Status Success

    Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes and straight leg raise.

    Time frame: 24 month

  2. Hip (Donor Site) Pain

    Time frame: 24 month

  3. General Health Status (SF-36)

    Time frame: 24 month

  4. Pain Status (back pain, leg pain)

    Time frame: 24 month

  5. Patient Satisfaction

    Time frame: 24 month

  6. Patient Global Perceived Effect

    Time frame: 24 month

  7. Overall Success

    Time frame: 24 month

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01494441
Lead sponsor
Medtronic Spinal and Biologics
Responsible party
Sponsor
First posted
Dec 19, 2011
Start date
May 1999
Primary completion
Mar 2003
Completion
Mar 2003
Last update
May 17, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion